3-methanesulfonylpropionitrile for treating inflammation and pain
The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
1. A method of reducing or alleviating the symptoms of localized manifestations of inflammation, comprising the steps of:
identifying a subject suffering from inflammation, and
topically administering to the subject a compound of 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt or solvate thereof, in an amount effective to treat inflammation, wherein said symptoms are characterized by acute or chronic swelling, pain, or redness.
2. The method according to claim 1 , wherein said compound is administered in a topical form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, suspension, or patch.
3. The method according to claim 2 , wherein said compound is in an amount of about 0.5-10% (w/w) in the topical form.
4. The method according to claim 3 , wherein the topical form comprises diethyleneglycol monoethylether.
5. A method of treating inflammation and/or pain, both associated with an inflammatory skeletal or muscular disease or condition, comprising the steps of:
identifying a subject in need thereof, and
topically administering to the subject 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt or solvate thereof, in an amount effective to treat the inflammation and/or pain, wherein the skeletal or muscular disease or condition is selected from the group consisting of: musculoskeletal sprains, musculoskeletal strains, gout, costochondritis, tendonitis, bursitis, and temporomandibular joint syndrome.
6. The method according to claim 5 , wherein said compound is administered in a topical form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, suspension, or patch.
7. The method according to claim 6 , wherein said topical form comprises the compound in an amount of about 0.5-10% (w/w).
8. A method of treating inflammation and/or pain, both associated with inflammatory joints, ligaments, tendons, bone, muscles, or fascia, comprising the steps of:
identifying a subject in need thereof, and
topically administering to the subject 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt or solvate thereof, in an amount effective to treat the inflammation and/or pain associated with joints, ligaments, tendons, bone, muscles, or fascia.
9. The method according to claim 8 , wherein said compound is administered in a topical form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, suspension, or patch.
10. The method according to claim 1 , wherein said symptoms are characterized by acute or chronic swelling.
11. The method according to claim 8 , wherein said compound is in an amount of about 0.5-10% (w/w) in the topical form.
12. The method according to claim 9 , wherein said topical form comprises diethyleneglycol monoethylether.
13. A method of treating pain associated with osteoarthritis, comprising the steps of:
identifying a subject in need thereof, and
topically administering to the subject 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt or solvate thereof, in an amount effective to treat the pain.
14. The method according to claim 13 , wherein said compound is administered in a topical form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, suspension, or patch.
15. The method according to claim 13 , wherein said compound is in an amount of about 0.5-10% (w/w) in the topical form.
16. The method according to claim 15 , wherein the topical form comprises diethyleneglycol monoethylether.